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Available online 18 March 2013 In the past 15 years, fragment-based lead discovery (FBLD) has been adopted widely throughout acade- 
mia and industry. The approach entails discovering very small molecular fragments and growing, merg- 
ing, or linking them to produce drug leads. Because the afﬁnities of the initial fragments are often low, 
detection methods are pushed to their limit s, leading to a variety of artifacts, false positives, and false 
negat ives that too often go unrecogni zed. This Digest discusses some of these problems and offers sug- 
gestions to avoid them. Although the primary focus is on FBLD, many of the lessons also apply to more 
establishe d approaches such as high-through put screening. 
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.An expert is a person who has made all the mistakes that can be 
made in a very narrow ﬁeld.
-Niels Bohr 
Fragment-b ased lead discovery (FBLD) is now widespread 
throughout academia and industry and has delivered more than 
two dozen drugs into clinical trials. The approach entails screening 
small libraries of very small molecules, typically less than 300 Da. 
Because there are fewer possible fragment-sized molecules than 
lead-sized or drug-sized molecules, chemical space can be explored 
much more efﬁciently than by traditional high-throughput screen- 
ing (HTS), even with a library of just a few thousand fragments. Frag- 
ments also make potentially better starting points for lead discovery 
because they contain fewer interfering moieties than HTS hits. The 
theory and practice of fragment- based lead discovery have been 
extensively reviewed in the literature as well as in ﬁve books. 1–5
Clearly the approach works, but that is not to say it is easy. This 
Digest focuses on an area we believe is still insufﬁciently appreci- 
ated: the myriad pitfalls and artifacts that can befall a fragment- 
screening program. For the sake of brevity, we have chosen to focus 
on the problems that can hinder or derail an experimental frag- 
ment screening campaign; a full discussion of issues around frag- 
ment library design, virtual fragment screening, and fragment 
evolution is best dealt with elsewhere. 
The ﬁrst challenge facing FBLD is simply ﬁnding fragments 
which can be conﬁdently identiﬁed as binding to the target. Having 
this conﬁdence in the validity of a fragment hit is key, particular ly since the risks of being misled by experimental artifacts are so 
much greater for fragments than when identifying tightly binding 
speciﬁc ligands. 
Since fragments generally have low afﬁnities for their targets—
sometimes weaker than 1 mM—it is essential to have sensitive and 
robust methods for detecting weak interactions . In 1996 research- 
ers at Abbott demonstrat ed that protein-d etected NMR could be 
used both to discover low afﬁnity fragments and inform how to 
link them; this paper is widely credited with popularizing the 
ﬁeld.6
Today many techniques are used to identify fragments (Fig. 1),7
each with its own strengths . Importantly, however, each of these 
techniqu es also has unique limitations. While expert users are gen- 
erally aware of these and readily pick out the signal from the noise, 
newcom ers are often deceived by spurious signals. This can lead to 
resource s wasted following up on artifacts. In the worst cases—
unfortun ately all too common—researchers may never realize that 
they have been chasing false positives, and publish their results. At 
best, this is an embarrassment, with the researchers sometimes 
none the wiser. At worst it can cause other research groups to 
waste their own resources. Two recent reports have demonstrat ed 
that literature results are not nearly as robust as one would 
hope.8,9 Although these were not focused on fragments, FBLD 
may be particularly prone to artifacts given its multidisciplinar y
nature and the number of neophytes in the ﬁeld.
All the pitfalls described below are known, yet they continue to 
show up on a regular basis in internal programs and, unfortunatel y, 
in the literature. Thus, they can be categorized as what Mike Hann 
memorab ly christened unknown knowns : ‘Those things that are 
Figure 2. Unstable molecules. Compound 1 oxidizes in DMSO and dimerizes to 
form 2 and 3. See text for details. 
Figure 1. Methods to ﬁnd fragments. These techniques were used to identify fragments, according to a poll on Practical Fragments in September 2011. There were 97 unique 
responses, and the average respondent used 2.4 different techniques. 
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learnt them, or forgotten about them, or more dangerously chosen 
to ignore.’ 10 It is our hope that this Digest can go some way 
towards transforming these pitfalls into known knowns. While 
most of the examples are taken from the literature, some have 
been reported in meetings, and others come from discussions with 
practitioners , who in some cases wish to remain anonymous; these 
are referenced as personal communi cations. 11
Compound behavior. In order to be conﬁdent in the results of a
fragment screen, you need to be conﬁdent in the quality of your 
hits. Before committing expensive chemistry resources, how do 
you guarantee that your fragment is what you think it is, that it re- 
mains what you think it is, and that it is actually doing what you 
think it is doing—i.e., making favorable interactions with a target? 
Compound identity . Although it may seem trivial, it is always 
worth checking to make sure that the compound you think you 
have is really what you have. A fragment may simply be incorrect ly 
registered in a database. More seriously, a purchased compound 
may not be what it says it is; both the authors have experienced 
this. If you are lucky, any follow-up chemistry will fail. If not, it 
might work, but not give you what you think you have. Depending 
on what your QC processes are, the error can propagate quite some 
way. In one example, a compound purchased for inclusion in a
fragment library was found to be an isomer of the structure 
claimed by the vendor; worryingly, despite unambiguou s data 
proving the catalog structure was incorrect, the vendor refused 
to remove the compound from sale ‘because no-one else had com- 
plained’ (personal communi cation). In another particularly notori- 
ous example, more than a dozen vendors were discovered to be 
selling the wrong isomer of the clinical stage kinase inhibitor 
bosutinib.12
Low-level impurities . Because fragment screening is typically 
performed at high concentratio ns, small amounts of reactive inter- 
mediates can wreak havoc: a 1% impurity will be present at 10 lM
if a screen is run at 1 mM. Characterizing fragments by NMR and 
HPLC-MS is useful, but silent impurities can still sneak past. Metals 
are often used in organic synthesis, and can sometimes co-purify 
with compounds . For example, residual silver was found to cause a number of false positives in one assay, 13 as has gadolinium. 14
Similarly , several assays at Roche were found to be sensitive to 
low micromolar levels of zinc, a contaminan t in a number of com- 
pounds.15 In fact, zinc binding was even detectable by surface plas- 
mon resonance. One of the projects was a fragment screen run at 
250 lm, and the researchers note that fragment screens, ‘which 
are typically run at much higher compound concentratio ns, should 
be more prone for false-positive signals from zinc and metal-co n- 
taminated compounds.’ 
It is possible for small amounts of potent impurities to contam- 
inate a chemical sample during synthesis , puriﬁcation, or com- 
pound management and plating. In one case, a fragment was 
contaminat ed with a trace of a potent generic kinase inhibitor, 
causing severely misleading results when that fragment was later 
screened against a kinase. Fortunately , in that instance, the use 
of orthogon al techniques identiﬁed the issue before signiﬁcant re- 
sources were engaged (personal communication).
Compoun d stability . Compounds can degrade over time, some- 
times quite unexpectedl y: medicinal chemists generally strive to 
make molecules that will be stable in vivo, so it can be disconcert- 
ing to ﬁnd that they fall apart during storage. One culprit is the 
commonl y used solvent DMSO, which is a mild oxidant. 16 For
example, pyrimidine derivatives such as compound 1 are colorless, 
but when dissolved in DMSO change color and oxidatively dimer- 
ize to form 2 and 3 within a matter of hours (Fig. 2).17 Since com- 
pounds are often stored for months or more as stock solutions in 
DMSO, this degradat ion can become a serious issue. In order to 
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LCMS is good practice. 18
In other cases, water is the problem—and because DMSO is 
hygroscopic, water is often (unintentionally) present in the com- 
pound stock solution. This can cause particular problems where 
DMSO stocks are subjected to freeze–thaw cycles. 19,20 Sandra Nel- 
son and co-workers showed that substantially more compound 
degradation occurred in a test set of compounds which were sub- 
jected to freeze–thaw cycles than the same compounds stored at 
room temperature for the same period of time. 21 The amount of 
water taken up by DMSO stocks can vary dramatical ly depending 
on factors such as the position of a well in a plate, which is an addi- 
tional complication in tracking compound stability. As an example, 
2-methyl-benz oxazole derivatives such as compound 4 can hydro- 
lytically open to produce compound 5 (Fig. 3). The reaction appears 
to be acid-catalyzed , and in fact the hydrochlori de salt can decom- 
pose even when stored as a solid. 22
Compound instability in aqueous solution can also give rise to 
erroneous assay data, particular ly where the assay has a pre-incu- 
bation period (as is often the case). In one case, a bicyclic com- 
pound (species A) formed a tricyclic compound (species B) when 
stored in DMSO. Species B readily reacted with water, and formed 
a third compound (species C) over the course of hours in aqueous 
solution (Fig. 4). For the target of interest, species B was the active 
species, but the concentration of species B varied dramatically Figure 3. Unstable molecules. Compound 4 is hydrolytically unstable. See text for 
details. 
Figure 4. Schematic of example of compound stability causing problems. depending on the details of the sample handling prior to the assay 
(personal communi cation).
Even when the compound is stable in aqueous solution, phe- 
nomena such as tautomerizati on should be considered. This is 
particular ly the case for fragments , where substruc tures of the 
hits are often used as pharmacoph ores for subsequent evolution. 
An example of this is a ketone-cont aining compound which, in 
the ligand observed NMR spectra, clearly bound only in the enol 
form (personal communicati on). Moreove r, compound solubility 
is often an issue at the high concentratio ns used in fragment 
screening . A recent analysis of fragments acquired from multiple 
commerc ial vendors found that 16% did not pass quality control 
standards set by Emerald Biostruct ures. About half of these 
failed due to solubility, with the remainder showing either deg- 
radation or impurities and a few with ambiguous or incorrect 
structure s. 23 Of course, solubility is critically dependent on 
experime ntal conditions; an acidic fragment may be highly solu- 
ble at neutral pH but much less so at the low pH required for 
assaying, say, a lysosoma l protein. This can also be an issue in 
crystallo graphy, where the ionic strength or pH required for 
crystallizati on can be substantially different to that used in 
assays.
Reactive molecules . Even if a molecule is stable, it may react 
covalently with biological targets. Of course, lots of drugs work 
in this manner, and there is a growing trend of designing such reac- 
tive molecule s, but you generally want to know this ahead of 
time.24,25 In a review by Gilbert Rishton, the functionalities in Fig-
ure 5 were reported to be potentially reactive; molecules contain- 
ing most of these are intentionally excluded from screening 
libraries for this reason. 26 However, this list is not comprehens ive, 
and as the next sections show, molecule s can pass cursory inspec- 
tion but still cause problems. 
PAINS. Most experienced medicinal chemists will look askance 
at the compound s in Figure 5, but not all problematic compound s
are obvious troublemak ers. After performi ng a number of high- 
throughput screens and ﬁnding that the same compounds hit 
many disparate targets, Jonathan Baell and Georgina Holloway 
christene d such molecules pan-assay interfere nce compound s, or 
PAINS; some of these substructur es are shown in Figure 6.14,27,28
A common feature of many PAINS is that they contain a Michael 
acceptor; rhodanines (Fig. 6 upper left) are a case in point. Such 
molecule s are soft electrophiles that can react with nucleophilic 
residues in proteins, either reversibly or irreversibl y. 29 Although
they can also bind non-cova lently, 30 their propensity to form cova- 
lent bonds makes them unsuitable for drugs or even probe mole- 
cules, as selectivity will likely confound interpretation of the 
biology.
Some of these molecule s are also photochemicall y reactive. For 
example Percy Carter and co-workers found that certain rhoda- 
nines and related molecules could form covalent adducts with a
protein under ambient illumination . Although some molecule s
exhibited weak reversible binding in the dark, others appeared to 
be complete ly dependent on light for their activity. 31,32
Unfortunate ly, molecules containing the moieties shown in Fig-
ure 6 are widely available commerciall y and thus found in numer- 
ous screening libraries; they often show up as hits, and too many 
researche rs are unaware of their promiscuous nature. Indeed, Baell 
has aptly described such molecules as ‘polluting the literature’ 
with peer-reviewed false positives. 
An example of how such molecules can be misleading has re- 
cently been described by R. Kiplin Guy and colleagues. SJ-17255 0
(compound 6 in Fig. 6) had initially been reported as an inhibitor 
of the p53-HDMX protein–protein interaction. 33 However, subse- 
quent detailed mechanistic work demonstrated that not only was 
it a covalent inhibitor, it was also sensitive to reducing agents 
and possibly exhibited some of its activity by aggregation (see sec- 
Figure 5. Reactive moieties. These functionalities are potentially reactive and should generally be avoided. 
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mechanism greatly complicates the interpretation of experiments 
using [SJ-172550] and limits its value as a lead compound for fur- 
ther development as a selective MDMX inhibitor.’ 34
Redox-active molecules . A particular ly nasty subset of PAINS are 
so-called redox cycling compound s. These molecules, many of 
which seem to be nitrogen- rich heterocycl es, can be reduced by Figure 6. Pan-assay interference compounds (PAINS). These moieties have been identiﬁ
lower right) contains an alkylidene bearing ﬁve-membered heterocycle (top row, seconcommon buffer components such as DTT or TCEP to form reactive 
species that spontaneou sly oxidize in air, producing hydrogen 
peroxide in the process (see conversion of compound s 9–10 in
Fig. 7). This in turn can readily oxidize proteins, particularly cys- 
teine residues. 35,36 Some of these molecules are fragment-sized .
They have shown up in a number of screens, and unfortunately 
their mechanism has not always been recognized . For example, ed as PAINS and should generally be avoided. Note that SJ-172550 (compound 6,
d from left).
Figure 8. Aggregators. Despite their small size, these molecules can form aggre- 
gates that nonspeciﬁcally inhibit enzymes and protein–protein interactions. 
Figure 7. Redox cyclers. Compounds 7–9 and 11 have been shown to generate 
hydrogen peroxide when exposed to reducing agents such as DTT or TCEP in the 
presence of air (middle).
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tion inhibitor, but ﬂat SAR, discrepancie s in different assays, and 
the presence of DTT in the assay buffer all suggest that this 
compound is acting by redox cycling. 37 Indeed, subsequent 
research identiﬁed this very molecule as a potent redox cycler. 38
Fortunately assays have been developed to weed out such com- 
pounds;39,40 as new compound s are acquired it is essential to test 
them for such activity, particularly if they contain unusual hetero- 
cyclic ring systems. 
Redox-active molecules and other PAINS are increasingly recog- 
nized as problematic, and Baell has recently released more than 
1000 functional group and PAINS ﬁlters that can be used to cull 
such compounds from libraries. 14
Aggregators. Even if molecules are stable, pure, and unreactive, 
they can still mislead: one of the most insidious problems is aggre- 
gation. Many small molecules can form microscop ic aggregat es in 
aqueous buffer, and these aggregates can non-speciﬁcally inhibit a
variety of assays. The higher the concentr ation, the more likely 
aggregates are to form, so fragment-scree ning is particularly sus- 
ceptible to this phenomenon. That said, aggregat ion can occur even 
at nanomolar concentratio ns of compounds. This phenomeno n was 
not reported in the literature until 2002, 41 but its frequent occur- 
rence probably dissuaded many people from pursuing low afﬁnity
fragments. Too often, unrecognize d aggregators produced exciting 
initial results that proved recalcitrant to attempts at optimization. 
Aggregation can occur with a wide variety of molecule s, includ- 
ing fragment- sized ones (Fig. 8). The easiest means to avoid this 
problem is to add a non-ionic detergent such as Triton X-100 or 
Tween to the assay; doing so will almost always cause a dramatic 
decrease in activity for aggregators, but should have little or no af- 
fect on legitimate binders. 42–44 In one example, a quantitative HTS 
screen of 70,563 molecule s found 1274 hits, of which 1204 lost 
activity in the presence of detergent. 45 However, detergent is not 
a panacea: Wells and co-workers described a class of molecules 
that form ﬁbrils, even in the presence of detergent. Procaspase 
molecules bind to the ﬁbrils, bringing them close together and 
apparently causing them to proteolytical ly activate one 
another.46,47
Aggregators typically show steep Hill slopes in dose–response
assays, and rarely show competitive enzyme kinetics; of course, some legitimate inhibitors also show these properties. Aggregates 
can also be detected using electron microscopy, FACS, or dynamic 
light-scatter ing, and can sometimes be centrifuged. Finally, com- 
pounds that aggregate sometimes show shallow SAR, meaning that 
relatively signiﬁcant structura l changes may have little effect on 
activity.48 Nonetheless , it is important to always remain vigilant: 
in one example, a miscommuni cation in the amount of detergent 
in the assay led to a compound series being optimized for aggrega- 
tion rather than binding. 49 Some of the best compounds in this ser- 
ies displayed IC 50 values of 200 nM under low-dete rgent 
condition s, but no activity at higher detergent levels. 
Aggregator s are probably one of the worst ‘pollutants’ in the 
chemical literature. For example, previously reported inhibitors 
of prostaglandin E2 synthase , including one that is sold commer- 
cially as a research tool, have recently been found to be aggrega- 
tors,50,51 calling into question any research done with these 
molecule s. Similarly, several reported inhibitors of the anticance r
target lactate dehydrogen ase A have also been unmasked as aggre- 
gators; a paper reporting one of them has already been cited more 
than 100 times. 52 Unfortunate ly these are not isolated examples. 
Both of the authors have repeatedly seen molecules reported in 
the literature that, upon testing, turned out to be aggregat ors. 
Research ers need to convince themselv es that their molecules 
are not aggregat ors, and reviewers and journal editors need to en- 
sure that papers are as rigorous about their assays as they are 
about compound quality. 
Assay behavior . Besides general problems that can occur with 
compound s and targets, each individual fragment-ﬁnding method 
has its own unhappy constella tion of artifacts, despite what boost- 
ers of a particular technology may say. Indeed, a key to success in 
fragment screening is to use multiple orthogonal methods and fo- 
cus on those hits that conﬁrm in different methods . This can be a
sobering exercise: in one recent case, 53 nuclear magnetic reso- 
nance (NMR) and surface plasmon resonance (SPR) screens of 
essentiall y the same library both yielded a number of hits, but very 
few of these were in common, and none of the crystallogra phically 
conﬁrmed hits were picked up in both the primary NMR and SPR 
screens. Techniqu e-speciﬁc problems are discussed below. 
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the gold standard technique for characterizi ng intermolecu lar 
interactions in solution, and was in fact the ﬁrst technique to 
demonstrat e that fragment-bas ed approaches to lead discovery 
could be practical. 6,54 Nonetheless , there are limitatio ns and poten- 
tial artifacts associate d with each of the different experime nts typ- 
ically used to identify ligands. To some extent these problems can 
be circumve nted by the application of multiple complemen tary 
NMR experiments , but the limitations of each method should be 
considered carefully when the aggregated data are analyzed. Some 
of the potential artifacts and issues associated with the more com- 
mon NMR binding experiments are detailed in Table 1.55
A common limitation with ligand-observed NMR techniques is 
that the experiments are typically run with a large molar excess 
of ligand over receptor. Thus, the experiment detects the effect 
on the bulk ligand population of interactions between ligand and 
receptor; if the ligand dissociation rate from the receptor is slow, 
the net effect on the bulk population will be small and no binding 
will be observed . In practical terms, this means that ligands which 
bind tighter than high nM to low lM, depending on the exchange 
dynamics, may be missed. While such fragments are likely to be 
quite rare, they are probably the most interesting! 
A second limitation with many of the ligand-obser ved NMR 
experiments is that no indication of the binding site is obtained. 
The use of a competitor ligand can provide some information ,
although partial displacement is frequently observed , and it is also 
possible for a ligand to cause allosteric displacemen t of an active- 
site probe. 
Finally, since fragment screens are often run at high concentra- 
tions, it is possible for fragments that contain acidic or basic moi- 
eties to actually change the pH of the solution, leading to chemical 
shift perturbation s which are simply the result of altered pH rather 
than fragment binding. 
X-ray crystallography . A picture is worth a thousand words, 
according to the old cliché, but in fragment optimization a picture 
can be far more valuable. Crystallograph ic data are considered the 
gold standard for moving compounds forward: seeing exactly how 
a fragment binds can provide ideas on how to improve the afﬁnity.
But by the same token, it is easy to forget that a beautiful molecu- 
lar model is just that—a model—and thus susceptible to artifacts 
and over-interpr etation. As Andrew Davis et al. noted, ‘many scien- 
tists who use structural information seem to be unaware of the fact 
that an X-ray crystal structure is one crystallo grapher’s subjectiv e
interpretation of an experimental electron density map expressed 
in terms of an atomic model.’ 57 For example, ambiguous or incom- Table 1
Experiment Species observed 
Protein observed NMR 
15N-1H HSQC Protein 
13C-1H HSQC Protein 
Ligand observed NMR 
STD Bound ligand (saturation occurs only in 
bound state)
Water-LOGSY Bound and free ligand (magnetization
transfer occurs 
in both free and bound states)
Relaxation ﬁltered 1D Free ligand (bound ligand is attenuated)
ILOE Ligands binding in close proximity to 
one-another 
TINS Free ligand (bound ligand is attenuated)
19F direct observe Free ligand (bound ligand is attenuated)
19F probe displacement Indirect effect of bound ligand (probe is 
displaced from bound state)plete electron density can result in ﬁtting small molecules or moi- 
eties in the wrong orientation. 58 In some cases simple inspection 
combined with chemical intuition could reveal the problem (for
example, if a primary amide is reversed, contacts with surrounding 
residues may not make sense), but in other cases, particularly if the 
crystal is soaked with a racemic mixture, structure s could be much 
harder to interpret. Sometimes solvent or buffer components are 
misinterpreted as the desired small molecule ligand. One group 
came close to publishing a structure of a fragment only to notice 
that the partial density was actually part of a long PEG chain run- 
ning through the binding site (personal communication). Unfortu- 
nately, such cases are not uncommon , and are not always caught 
before being published. 59
Ironically , these problems seem to be exacerbated for the 
more interesting structure s. After analyzing all the structure s
deposited in the Protein Data Bank (PDB), Eric Brown and S. 
Ramaswa my reported that ‘the most striking result is the associ- 
ation between structure quality and the journal in which the 
structure was ﬁrst published. The worst offenders are the appar- 
ently high-impact general science journals. The rush to publish 
high-imp act work in the competitive atmosphere may have led 
to the prolifera tion of poor-quality structures.’ 60 Even journals 
such as Nature are not immune, as a recent example in which 
a structure was retracted from the PDB illustrate s. 61 In another 
recent study, only 17% of 728 crystal structures previousl y used 
to validate computational docking methods passed a rigorous set 
of quality criteria. 59
Another issue is that crystallogra phy usually produces a single, 
static structure, and this could be signiﬁcantly different than the 
structure adopted by the protein–ligand complex in solution. 
Moreove r, individual molecules in a crystal may adopt different 
conformations , but these may be averaged out during crystallo -
graphic reﬁnement. As Mark DePristo et al. noted, ‘in many cases 
the problem is not selecting the best single conformation, but that 
several conformations are equally plausible interpretations of the 
electron- density map, especiall y at lower resolution. ’62
Crystal packing contacts between individual protein molecule s
can also affect the binding sites of ligands. In some cases this 
may not be obvious when looking at the structure of just a single 
protein–ligand interaction, as the ligand could make direct or 
water-m ediated interactio ns with a different (symmetry-related)
protein in the crystal lattice. 63
Perhaps the most fundamenta l but easily overlook ed problem 
with crystallograph ic data is the fact that it provides no afﬁnity
informat ion. Given the high concentratio ns of fragments some- Limitations or potential artifacts 
Shifts resulting from solvent binding or pH changes. Spectral overlap 
Shifts resulting from solvent binding or pH changes. Spectral overlap 
False positives resulting from direct irradiation of ligand. False negatives 
resulting from incomplete saturation of protein. No binding site information 
False positives from self-association of ligands. Contribution from both free 
and bound populations. Chemical exchange. No binding site information 55
False positives or negatives resulting from unusually short or long relaxation 
rates. No binding site information 
Aggregation of ligands can appear to be positive signal. 56 No binding site 
information 
Severe line broadening from matrix. Heterogeneous phase 
Requirement 
for reference protein. No binding site information 
Requirement for 19F in fragment. No binding site information 
Requirement for labeled probe molecule 
2850 B. J. Davis, D. A. Erlanson / Bioorg. Med. Chem. Lett. 23 (2013) 2844–2852times used for soaking experime nts, it is possible to obtain co-crys- 
tal structures of fragments that show no detectab le binding or inhi- 
bition in other assays. While these can be valuable, they can also 
identify fragments that bind so weakly that even heroic efforts 
would be wasted on advancing them. 
On the other end of the spectrum, even well-behaved fragments 
may fail to yield crystallograph ic structures for a variety of reasons. 
The afﬁnity and/or solubility of fragments in crystallization or 
soaking buffers may be considerably less than in other buffers. Of- 
ten multiple crystal forms or soaking conditions may need to be 
investigated , and even then some binding sites may be occluded 
by crystal contacts and thus be inaccessible. Although such false 
negatives will not lead to the same wasted effort as do false posi- 
tives, an over-reliance on crystallograph y could cause promising 
chemical series to be prematurely abandon ed. 
Isothermal titration calorimet ry (ITC). ITC can provide thermod y- 
namic binding parameters (DG, DH, and DS) for protein–ligand 
interactions . When performed carefully, this is an extremely pow- 
erful and accurate technique. However, systematic errors, such as 
incorrectly measured concentrations or failure to properly account 
for heats of dilution, can signiﬁcantly affect the results. 64 In one 
notable example, 14 separate labs were each provided with a mod- 
el system, bovine carbonic anhydrase II (CA II) and 4-carboxyben- 
zenesulfona mide (CBS), and asked to use ITC to determine the 
enthalpy of binding and binding constant. 65 Although most of the 
values clustered relatively close together, there were signiﬁcant
outliers: the DH ranged from 4.3 to 15.4 kcal/mol (with the 
average being 10.4 kcal/mol) and even the stoichiometry ranged 
from 0.55 to 1.25 (with the average being 0.94). The fact that such 
variation is observed for a robust, well-studied model system in 
which participants were all using the very same reagents is a use- 
ful reminder that all data needs to be taken with a grain of salt, 
particularly in less well-deﬁned systems. 
Surface-plasm on resonance (SPR). As seen in Figure 1, SPR has be- 
come a dominant method for ﬁnding fragments. Typically, a target 
protein is immobilized on a chip, and varying concentrations of a
small molecule are allowed to ﬂow over it. When a ligand binds 
to the protein it causes a change in the reﬂective properties that 
depends on the ratio of the ligand mass to the protein mass. 
Though small fragments require very sensitive detection, many 
commerciall y available instruments are currently suitable for frag- 
ment screening. 
Because SPR experiments are straightfo rward to set up and run, 
it is easy for novices to make mistakes or misinterpret their data. 
As Rebecca Rich and David Myszka noted after surveying 1413 pa- 
pers that used SPR in 2008, ‘less than 30% would pass the require- 
ments for high-school chemistry’. 66 An analysis of the 1514 
publications in 2009 that used SPR was equally discouraging: only 
20% were given a passing grade by a panel of 22 experts. 67 Fortu-
nately there are now good resources for how to establish an SPR 
screen; one of the best is a nearly 50-page book chapter by Tony 
Giannetti.68
Some of the same aggregat ion phenomena that disrupt bio- 
chemical screens can also muddle SPR screens. The problem is that 
aggregates can cause an SPR signal, and this can be misinterpreted 
as fragment binding by inexperienced users. 69 That said, legitimate 
fragments too can sometimes cause problems. For example, a frag- 
ment shown to bind to the enzyme Pin1 by both NMR and crystal- 
lography showed super-stoichio metric binding by SPR. 70 In this 
case the fragment was a relatively ‘ﬂat’ aromatic heterocycle, and 
analogs that incorporated a stereocenter showed better behavior. 
It is possible that such ‘three-dimension al’ fragments may gener- 
ally be less prone to aggregation , though the authors are unaware 
of any systematic study. Indeed, some fragments may behave 
poorly under some condition s with some targets but be well be- 
haved with different targets. For example, a negatively charged protein may cause cationic fragments to bind nonspeciﬁcally
around it, a phenomeno n that Markku Hämäläinen calls ‘selective 
promiscu ous binders.’ 71
In theory, SPR can provide on-rates and off-rates, but in practice 
binding kinetics are rarely observed for fragments due to their low 
afﬁnity. In fact, unusually slow dissociation can be a sign of aggre- 
gation.69 That said, small fragment-sized molecules can show high 
afﬁnity binding and slow kinetics; one 14-atom ligand of the pro- 
tein D-amino acid oxidase (DAAO) binds with low nanomolar afﬁn-
ity with an off-rate on the order of 0.07 h1.72 In another example, 
a fragment identiﬁed as binding to a kinase by ligand-obser ved 
NMR was found to have a dissociation constant of 90 nM by SPR. 73
Another question, not limited to SPR, is how speciﬁc a fragment 
should be. Within a given target class, for example kinases, it is 
possible to optimize a promiscuous fragment to a highly selective 
molecule (though it is also possible to start with a selective frag- 
ment and lose selectivity).74 However , sometimes an unrelated 
protein is used as a counter-scr een to weed out promiscuous bind- 
ers; this could unnecessari ly exclude useful fragments that just 
happen to bind to both targets. For example, in a recent study, sev- 
eral fragments were shown by SPR to bind to two completely unre- 
lated proteins, and these were initially classiﬁed as promiscuous .
However , subsequent crystallogra phy demonstrated that they did 
in fact bind to the protein of interest, HIV-1 integrase. 53 Indeed,
due to the fact that fragments generally lack ‘molecular complex- 
ity’ it makes sense that certain privileged pharmacoph ores may 
bind to multiple proteins. 75
Biochemic al and functional assays . Enzymatic assays and binding 
assays such as ﬂuorescence polarization (FP) or ﬂuorescence reso- 
nance energy transfer (FRET) assays are simple and fast, and often 
useful as primary screening methods, but one needs to be willing 
to wade through a lot of false positives. For example, in an inhibi- 
tion assay of the enzyme Pin1, 40 hits were identiﬁed, but only ﬁve
could be conﬁrmed by NMR. 76 Biochemi cal assays can fall victim to 
the full panoply of pathological impurities, reactive molecules, and 
aggregat ors discussed above. Finally, in the case of cascade assays 
involving multiple proteins one needs to verify that hits actually 
inhibit the target of interest rather than, say, an enzyme involved 
in producing a signal. 
Thermal shift . As shown in Figure 1, thermal shift assays are 
widely used for fragment screening. A key advantage is that they 
are fast and inexpensive to perform: a protein is mixed with a
putative ligand, heated, and the ‘melting temperature’ of the pro- 
tein is measured; ligands typically stabilize their hosts against 
thermal denaturati on, so molecule s that raise the melting temper- 
ature are considered hits. 77 Operationally, the assay is typically 
conducte d by adding a dye that changes its ﬂuorescence propertie s
when it binds to the denatured form of a protein. The screen can be 
conducte d in microtiter plates using widely available instruments 
designed for RT-PCR. 
Of all the methods for ﬁnding fragments, thermal shift assays 
seem to be the most controversial. At the FBLD 2012 meeting in 
San Francisco, some speakers described them as extremely unreli- 
able, while others found them to be quite useful. Certainly some 
proteins are more suited to the technique than others. However, 
one needs to be cautious about using the techniqu e as a primary 
assay: in a screen for stabilizers of mutant p53, Fersht and co- 
workers found a much lower hit rate than for an NMR method, 
and suggested that ﬂuorescence quenchin g by fragments could 
lead to a high false-neg ative rate. 78 On a similar note, 14 of 15 frag- 
ments that bound to PARP15 as assessed by SPR were conﬁrmed by 
NMR, while only one was conﬁrmed by differential scanning ﬂuo-
rimetry.79 False positives are an issue too: only 26 of 56 fragments 
that stabilized CYP121 towards thermal denaturation were con- 
ﬁrmed by NMR to bind at the active site, though others may have 
bound outside the active site. 80
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the potential pitfalls, particularly if you are new to the technology 
or to fragment-based screening. Ideally, fragment hits should be 
conﬁrmed in at least two completely different assays before 
embarking on any sort of chemistry optimization. And of course, 
even after you have found validated fragments , there are many 
challenges to advancing these from low afﬁnity ligands to leads 
and, eventually, to a clinical candidate. 
To conclude, every step in any fragment screen can yield mis- 
leading information . Knowing about possible problems can help 
you recognize them before investing additional resource s or 
embarrassin g yourself publicly. Although it may seem paranoid, 
it is probably safest to assume any hit is guilty of being an artifact 
until proven innocent. As Richard Feynman noted, ‘The ﬁrst princi- 
ple is that you must not fool yourself–and you are the easiest per- 
son to fool. So you have to be very careful about that.’ Hopefully 
this Digest will help to illuminate some of the darker aspects of 
fragment screening. Only then can the real fun can begin. 
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